questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Transferases
Glycosyltransferase
Pentosyltransferases
ADP ribose transferases
ADP ribose transferases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Gain of Function Mutation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "ADP ribose transferases : Questions médicales les plus fréquentes",
"headline": "ADP ribose transferases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les ADP ribose transferases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-30",
"dateModified": "2025-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "ADP ribose transferases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pentosyltransferases",
"url": "https://questionsmedicales.fr/mesh/D010430",
"about": {
"@type": "MedicalCondition",
"name": "Pentosyltransferases",
"code": {
"@type": "MedicalCode",
"code": "D010430",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NAD nucleosidase",
"alternateName": "NAD+ Nucleosidase",
"url": "https://questionsmedicales.fr/mesh/D009244",
"about": {
"@type": "MedicalCondition",
"name": "NAD nucleosidase",
"code": {
"@type": "MedicalCode",
"code": "D009244",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.660"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "ADP-ribosyl cyclase",
"alternateName": "ADP-ribosyl Cyclase",
"url": "https://questionsmedicales.fr/mesh/D036541",
"about": {
"@type": "MedicalCondition",
"name": "ADP-ribosyl cyclase",
"code": {
"@type": "MedicalCode",
"code": "D036541",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.660.060"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Poly(ADP-ribose) polymerases",
"alternateName": "Poly(ADP-ribose) Polymerases",
"url": "https://questionsmedicales.fr/mesh/D011065",
"about": {
"@type": "MedicalCondition",
"name": "Poly(ADP-ribose) polymerases",
"code": {
"@type": "MedicalCode",
"code": "D011065",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.690"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Poly (ADP-Ribose) polymerase-1",
"alternateName": "Poly (ADP-Ribose) Polymerase-1",
"url": "https://questionsmedicales.fr/mesh/D000071137",
"about": {
"@type": "MedicalCondition",
"name": "Poly (ADP-Ribose) polymerase-1",
"code": {
"@type": "MedicalCode",
"code": "D000071137",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.690.420"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Tankyrases",
"alternateName": "Tankyrases",
"url": "https://questionsmedicales.fr/mesh/D038501",
"about": {
"@type": "MedicalCondition",
"name": "Tankyrases",
"code": {
"@type": "MedicalCode",
"code": "D038501",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.690.840"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "ADP ribose transferases",
"alternateName": "ADP Ribose Transferases",
"code": {
"@type": "MedicalCode",
"code": "D036002",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Anthony K L Leung",
"url": "https://questionsmedicales.fr/author/Anthony%20K%20L%20Leung",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA."
}
},
{
"@type": "Person",
"name": "Morgan Dasovich",
"url": "https://questionsmedicales.fr/author/Morgan%20Dasovich",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA."
}
},
{
"@type": "Person",
"name": "Mohsen Badiee",
"url": "https://questionsmedicales.fr/author/Mohsen%20Badiee",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205."
}
},
{
"@type": "Person",
"name": "Yong Zhang",
"url": "https://questionsmedicales.fr/author/Yong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States."
}
},
{
"@type": "Person",
"name": "Sua Myong",
"url": "https://questionsmedicales.fr/author/Sua%20Myong",
"affiliation": {
"@type": "Organization",
"name": "Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Case Report: PROS1 (c.76+2_76+3del) pathogenic mutation causes pulmonary embolism.",
"datePublished": "2024-10-11",
"url": "https://questionsmedicales.fr/article/39465133",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fcvm.2024.1459579"
}
},
{
"@type": "ScholarlyArticle",
"name": "Derivation of induced pluripotent stem cell from a Baraitser-Winter Cerebrofrontofacial syndrome with ACTB mutation.",
"datePublished": "2024-10-09",
"url": "https://questionsmedicales.fr/article/39437565",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.scr.2024.103577"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nodule-specific NRF2-targeted upregulation in patients with KEAP1 mutations and familial nontoxic multinodular goiter.",
"datePublished": "2024-10-07",
"url": "https://questionsmedicales.fr/article/39373520",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1210/clinem/dgae699"
}
},
{
"@type": "ScholarlyArticle",
"name": "Discovery of Oral Degraders of the ROS1 Fusion Protein with Potent Activity against Secondary Resistance Mutations.",
"datePublished": "2024-10-03",
"url": "https://questionsmedicales.fr/article/39361251",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.jmedchem.4c01205"
}
},
{
"@type": "ScholarlyArticle",
"name": "No evidence of mutations associated with anticoagulant resistance in gene Vkorc1 in brown and black rats from Barcelona.",
"datePublished": "2024-09-26",
"url": "https://questionsmedicales.fr/article/39341232",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.scitotenv.2024.176321"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycosyltransferase",
"item": "https://questionsmedicales.fr/mesh/D016695"
},
{
"@type": "ListItem",
"position": 6,
"name": "Pentosyltransferases",
"item": "https://questionsmedicales.fr/mesh/D010430"
},
{
"@type": "ListItem",
"position": 7,
"name": "ADP ribose transferases",
"item": "https://questionsmedicales.fr/mesh/D036002"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : ADP ribose transferases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur ADP ribose transferases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur ADP ribose transferases",
"description": "Comment diagnostiquer une dysfonction des ADP ribose transferases ?\nQuels marqueurs biochimiques sont associés aux ADP ribose transferases ?\nY a-t-il des tests spécifiques pour les ADP ribose transferases ?\nQuels symptômes peuvent indiquer un problème avec ces enzymes ?\nLes tests d'imagerie sont-ils utiles pour ces enzymes ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Gain+of+Function+Mutation&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur ADP ribose transferases",
"description": "Quels symptômes sont liés à une déficience en ADP ribose transferases ?\nPeut-on observer des symptômes neurologiques ?\nLes symptômes varient-ils selon le type d'enzyme ?\nY a-t-il des symptômes cutanés associés ?\nLes symptômes sont-ils toujours présents ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Gain+of+Function+Mutation&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur ADP ribose transferases",
"description": "Peut-on prévenir les dysfonctionnements des ADP ribose transferases ?\nY a-t-il des facteurs environnementaux à éviter ?\nLes dépistages réguliers sont-ils recommandés ?\nL'exercice physique aide-t-il à prévenir ces dysfonctionnements ?\nLes vaccinations ont-elles un rôle préventif ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Gain+of+Function+Mutation&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur ADP ribose transferases",
"description": "Quels traitements existent pour les dysfonctionnements enzymatiques ?\nLes suppléments peuvent-ils aider ?\nY a-t-il des traitements expérimentaux ?\nLes traitements sont-ils personnalisés ?\nLes traitements sont-ils curatifs ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Gain+of+Function+Mutation&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur ADP ribose transferases",
"description": "Quelles complications peuvent survenir avec ces dysfonctionnements ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies cardiovasculaires ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles prévisibles ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Gain+of+Function+Mutation&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur ADP ribose transferases",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge est-il un facteur de risque ?\nLe stress a-t-il un impact sur ces enzymes ?\nLes antécédents familiaux influencent-ils le risque ?\nL'alimentation joue-t-elle un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Gain+of+Function+Mutation&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des ADP ribose transferases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses biochimiques peuvent être utilisés pour évaluer leur activité."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biochimiques sont associés aux ADP ribose transferases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'ADP-ribose libre et de protéines modifiées peuvent servir de marqueurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests spécifiques pour les ADP ribose transferases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques spécifiques peuvent mesurer l'activité des ADP ribose transferases."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec ces enzymes ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans la réparation de l'ADN ou des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests d'imagerie sont-ils utiles pour ces enzymes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les tests d'imagerie ne sont pas utilisés pour diagnostiquer les dysfonctionnements enzymatiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une déficience en ADP ribose transferases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la réparation de l'ADN, des maladies neurodégénératives et des cancers."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cognitifs et des problèmes de mémoire peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type d'enzyme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, différents types d'ADP ribose transferases peuvent entraîner des symptômes variés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent apparaître en raison de troubles métaboliques liés aux enzymes."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré une dysfonction enzymatique."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des ADP ribose transferases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines et à des radiations peut affecter l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages peuvent être utiles pour les personnes à risque élevé de maladies associées."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à prévenir ces dysfonctionnements ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la santé cellulaire et enzymatique."
}
},
{
"@type": "Question",
"name": "Les vaccinations ont-elles un rôle préventif ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les vaccinations ne sont pas directement liées à la prévention des dysfonctionnements enzymatiques."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les dysfonctionnements enzymatiques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des médicaments ciblés peuvent être envisagés."
}
},
{
"@type": "Question",
"name": "Les suppléments peuvent-ils aider ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments d'ADP-ribose peuvent être envisagés, mais leur efficacité n'est pas prouvée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des essais cliniques sur des inhibiteurs spécifiques des ADP ribose transferases sont en cours."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction du type de dysfonctionnement enzymatique."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils curatifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la plupart des traitements visent à gérer les symptômes plutôt qu'à guérir la condition."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces dysfonctionnements ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cancers, des maladies auto-immunes et des troubles neurologiques peuvent se développer."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies cardiovasculaires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études montrent un lien entre dysfonctionnement enzymatique et maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement altérer la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être anticipées en fonction des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs génétiques, l'exposition à des toxines et le mode de vie jouent un rôle."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter l'activité des ADP ribose transferases."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur ces enzymes ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress oxydatif peut altérer l'activité des ADP ribose transferases."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies liées peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en antioxydants peut réduire le risque de dysfonctionnement enzymatique."
}
}
]
}
]
}
Genetic variation plays an extremely important pathogenic role in the development of venous thromboembolism (VTE). Genetic protein S (PS) deficiency caused by PROS1 gene mutation is an important risk ...
In this case, we report a 28-year-old male patient who developed a severe pulmonary embolism during his visit. The patient had experienced one month of chest pains, coughing and hemoptysis symptoms. C...
Hereditary thrombophilia caused by mutations in the PROS1 (c.76+2_76+3del) gene is extremely rare. In clinical practice, heparin and rivaroxaban treatment are beneficial....
Baraitser-Winter Cerebrofrontofacial syndrome (BWCFF, OMIM: 243310) is a rare congenital developmental disorder marked by distinct facial dysmorphisms, coloboma, diminutive stature, and cognitive impa...
Kelch-like ECH-associated protein 1 (KEAP1) is associated with nuclear factor erythroid-2 related factor 2 (NRF2) and promotes NRF2 degradation in normal conditions. Genetic abnormality in KEAP1 is a ...
This study assessed the clinical and molecular findings concerning nodular formation in the thyroid gland of patients harboring KEAP1 germline mutations....
Next-generation sequencing analysis targeting goiter-associated genes was performed on 39 patients with familial multinodular goiter. The expression of NRF2-targeted genes from surgical thyroid specim...
We found five probands with pathogenic heterozygous mutations in KEAP1 (p.Q86*, p.L136P, p.V411fs, p.R415C, and p.R483H), which had no meaningful concomitance with mutations of other goiter-associated...
KEAP1 germline heterozygous mutations exert excessive NRF2 activity in the thyroid gland and may confer cytoprotective effects even under abundant reactive oxygen species associated with thyroid hormo...
The development of therapeutic resistance in the majority of patients limits the long-term benefit of ROS1 inhibitor treatment. On-target mutations of the ROS1 kinase domain confer resistance to crizo...
Synanthropic rodents such as the brown rat (Rattus norvegicus) and black rat (Rattus rattus) are a source of disturbance in urban areas and the focus of control programs. Control measures often rely o...
Insecticide resistance in the bed bug...
Invasive cervical cancers (ICC), caused by HPV infections, have a heterogeneous molecular landscape. We investigate the detection, timing, and HPV type specificity of somatic mutations in 3929 HPV-pos...
This review offers an in-depth analysis of mitochondrial DNA (mtDNA) mutations in colorectal cancer stem cells (CSCs), emphasizing their significant impact on tumor dynamics and potential therapeutic ...
Research into the pathophysiology of Parkinson's disease (PD) is a fast-paced pursuit, with new findings about PD and other synucleinopathies being made each year. The involvement of various lysosomal...
Pancreatic cancer is associated with an oncogenic KRAS mutation in approximately 90% of cases. However, a non-negligible proportion of pancreatic cancer cases harbor wild-type KRAS (KRAS-WT). This stu...